Mufg Securities Americas Inc. Takes Position in Amgen Inc. (NASDAQ:AMGN)

Mufg Securities Americas Inc. acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 7,936 shares of the medical research company’s stock, valued at approximately $2,068,000.

Several other large investors have also recently modified their holdings of the company. Malaga Cove Capital LLC increased its position in shares of Amgen by 4.4% during the fourth quarter. Malaga Cove Capital LLC now owns 15,739 shares of the medical research company’s stock worth $4,102,000 after purchasing an additional 661 shares in the last quarter. Nissay Asset Management Corp Japan ADV increased its position in Amgen by 5.6% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 121,718 shares of the medical research company’s stock valued at $31,969,000 after buying an additional 6,489 shares in the last quarter. NorthRock Partners LLC increased its position in Amgen by 143.3% during the 4th quarter. NorthRock Partners LLC now owns 10,285 shares of the medical research company’s stock valued at $2,681,000 after buying an additional 6,057 shares in the last quarter. OMERS ADMINISTRATION Corp raised its stake in Amgen by 12.6% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 24,166 shares of the medical research company’s stock valued at $6,299,000 after buying an additional 2,705 shares during the last quarter. Finally, Obermeyer Wealth Partners boosted its holdings in Amgen by 1.3% in the fourth quarter. Obermeyer Wealth Partners now owns 4,289 shares of the medical research company’s stock worth $1,118,000 after acquiring an additional 57 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other news, EVP David M. Reese sold 8,711 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the completion of the sale, the executive vice president now directly owns 62,147 shares in the company, valued at $18,222,743.34. The trade was a 12.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.76% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Bank of America upped their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday, March 5th. Piper Sandler boosted their target price on shares of Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Royal Bank of Canada decreased their price target on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Cantor Fitzgerald started coverage on Amgen in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $305.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $310.23.

Amgen Trading Down 1.6%

Amgen stock opened at $270.45 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The firm has a market cap of $145.42 billion, a PE ratio of 35.82, a P/E/G ratio of 2.63 and a beta of 0.51. The stock’s 50 day simple moving average is $294.29 and its two-hundred day simple moving average is $289.08. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the prior year, the firm posted $3.96 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.52%. Amgen’s payout ratio is 86.86%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.